446 related articles for article (PubMed ID: 27579675)
21. Untargeted LC-HRMS-Based Metabolomics for Searching New Biomarkers of Pancreatic Ductal Adenocarcinoma: A Pilot Study.
Ríos Peces S; Díaz Navarro C; Márquez López C; Caba O; Jiménez-Luna C; Melguizo C; Prados JC; Genilloud O; Vicente Pérez F; Pérez Del Palacio J
SLAS Discov; 2017 Apr; 22(4):348-359. PubMed ID: 27655283
[TBL] [Abstract][Full Text] [Related]
22. Identification of Small Proteins and Peptides in the Differentiation of Patients with Intraductal Mucinous Neoplasms of the Pancreas, Chronic Pancreatitis and Pancreatic Adenocarcinoma.
Fania C; Pezzilli R; Melzi d'Eril G; Gelfi C; Barassi A
Dig Dis Sci; 2018 Apr; 63(4):920-933. PubMed ID: 29417328
[TBL] [Abstract][Full Text] [Related]
23. Digital PCR-based plasma cell-free DNA mutation analysis for early-stage pancreatic tumor diagnosis and surveillance.
Okada T; Mizukami Y; Ono Y; Sato H; Hayashi A; Kawabata H; Koizumi K; Masuda S; Teshima S; Takahashi K; Katanuma A; Omori Y; Iwano H; Yamada M; Yokochi T; Asahara S; Kawakubo K; Kuwatani M; Sakamoto N; Enomoto K; Goto T; Sasajima J; Fujiya M; Ueda J; Matsumoto S; Taniue K; Sugitani A; Karasaki H; Okumura T
J Gastroenterol; 2020 Dec; 55(12):1183-1193. PubMed ID: 32939577
[TBL] [Abstract][Full Text] [Related]
24. A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer.
Balasenthil S; Huang Y; Liu S; Marsh T; Chen J; Stass SA; KuKuruga D; Brand R; Chen N; Frazier ML; Jack Lee J; Srivastava S; Sen S; McNeill Killary A
J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376184
[TBL] [Abstract][Full Text] [Related]
25. Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma.
Wang X; Li Y; Tian H; Qi J; Li M; Fu C; Wu F; Wang Y; Cheng D; Zhao W; Zhang C; Wang T; Rao J; Zhang W
BMC Cancer; 2014 Aug; 14():578. PubMed ID: 25106741
[TBL] [Abstract][Full Text] [Related]
26. Circulating Protein Biomarkers for Use in Pancreatic Ductal Adenocarcinoma Identification.
Lindgaard SC; Sztupinszki Z; Maag E; Chen IM; Johansen AZ; Jensen BV; Bojesen SE; Nielsen DL; Hansen CP; Hasselby JP; Nielsen KR; Szallasi Z; Johansen JS
Clin Cancer Res; 2021 May; 27(9):2592-2603. PubMed ID: 33737308
[TBL] [Abstract][Full Text] [Related]
27. Inflammatory cytokines and combined biomarker panels in pancreatic ductal adenocarcinoma: Enhancing diagnostic accuracy.
Kruger D; Yako YY; Devar J; Lahoud N; Smith M
PLoS One; 2019; 14(8):e0221169. PubMed ID: 31415645
[TBL] [Abstract][Full Text] [Related]
28. High-density and targeted glycoproteomic profiling of serum proteins in pancreatic cancer and intraductal papillary mucinous neoplasm.
Aronsson L; Andersson R; Bauden M; Andersson B; Bygott T; Ansari D
Scand J Gastroenterol; 2018 Dec; 53(12):1597-1603. PubMed ID: 30509115
[TBL] [Abstract][Full Text] [Related]
29. Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma.
Takayama R; Nakagawa H; Sawaki A; Mizuno N; Kawai H; Tajika M; Yatabe Y; Matsuo K; Uehara R; Ono K; Nakamura Y; Yamao K
J Gastroenterol; 2010; 45(1):52-9. PubMed ID: 19789838
[TBL] [Abstract][Full Text] [Related]
30. Analysis of IGF and IGFBP as prognostic serum biomarkers for adrenocortical carcinoma.
Patel D; Ellis R; Howard B; Boufraqech M; Gara SK; Zhang L; Quezado MM; Nilubol N; Kebebew E
Ann Surg Oncol; 2014 Oct; 21(11):3541-7. PubMed ID: 24833102
[TBL] [Abstract][Full Text] [Related]
31. Potential biomarkers for early detection of pancreatic ductal adenocarcinoma.
Kriz D; Ansari D; Andersson R
Clin Transl Oncol; 2020 Dec; 22(12):2170-2174. PubMed ID: 32447642
[TBL] [Abstract][Full Text] [Related]
32. A new panel of pancreatic cancer biomarkers discovered using a mass spectrometry-based pipeline.
Liu X; Zheng W; Wang W; Shen H; Liu L; Lou W; Wang X; Yang P
Br J Cancer; 2017 Dec; 117(12):1846-1854. PubMed ID: 29123261
[TBL] [Abstract][Full Text] [Related]
33. Updates and Critical Evaluation on Novel Biomarkers for the Malignant Progression of Intraductal Papillary Mucinous Neoplasms of the Pancreas.
Moris D; Damaskos C; Spartalis E; Papalampros A; Vernadakis S; Dimitroulis D; Griniatsos J; Felekouras E; Nikiteas N
Anticancer Res; 2017 May; 37(5):2185-2194. PubMed ID: 28476781
[TBL] [Abstract][Full Text] [Related]
34. Trefoil factor(s) and CA19.9: A promising panel for early detection of pancreatic cancer.
Jahan R; Ganguly K; Smith LM; Atri P; Carmicheal J; Sheinin Y; Rachagani S; Natarajan G; Brand RE; Macha MA; Grandgenett PM; Kaur S; Batra SK
EBioMedicine; 2019 Apr; 42():375-385. PubMed ID: 30956167
[TBL] [Abstract][Full Text] [Related]
35. Quantitative targeted absolute proteomics-based large-scale quantification of proline-hydroxylated α-fibrinogen in plasma for pancreatic cancer diagnosis.
Yoneyama T; Ohtsuki S; Ono M; Ohmine K; Uchida Y; Yamada T; Tachikawa M; Terasaki T
J Proteome Res; 2013 Feb; 12(2):753-62. PubMed ID: 23298340
[TBL] [Abstract][Full Text] [Related]
36. Serum tumor markers not useful in screening patients with pancreatic mucinous cystic lesions associated with malignant changes.
Pezzilli R; Calculli L; Melzi d'Eril G; Barassi A
Hepatobiliary Pancreat Dis Int; 2016 Oct; 15(5):553-557. PubMed ID: 27733327
[TBL] [Abstract][Full Text] [Related]
37. A migration signature and plasma biomarker panel for pancreatic adenocarcinoma.
Balasenthil S; Chen N; Lott ST; Chen J; Carter J; Grizzle WE; Frazier ML; Sen S; Killary AM
Cancer Prev Res (Phila); 2011 Jan; 4(1):137-49. PubMed ID: 21071578
[TBL] [Abstract][Full Text] [Related]
38. Elevated CEA and CA19-9 serum levels independently predict advanced pancreatic cancer at diagnosis.
van Manen L; Groen JV; Putter H; Vahrmeijer AL; Swijnenburg RJ; Bonsing BA; Mieog JSD
Biomarkers; 2020 Mar; 25(2):186-193. PubMed ID: 32009482
[No Abstract] [Full Text] [Related]
39. Circulating IGF system and treatment outcome in epithelial ovarian cancer.
Huang YF; Cheng WF; Wu YP; Cheng YM; Hsu KF; Chou CY
Endocr Relat Cancer; 2014 Apr; 21(2):217-29. PubMed ID: 24273235
[TBL] [Abstract][Full Text] [Related]
40. High Detection Rates of Pancreatic Cancer Across Stages by Plasma Assay of Novel Methylated DNA Markers and CA19-9.
Majumder S; Taylor WR; Foote PH; Berger CK; Wu CW; Mahoney DW; Bamlet WR; Burger KN; Postier N; de la Fuente J; Doering KA; Lidgard GP; Allawi HT; Petersen GM; Chari ST; Ahlquist DA; Kisiel JB
Clin Cancer Res; 2021 May; 27(9):2523-2532. PubMed ID: 33593879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
